David Cruikshank is a Partner at ARCH Venture Partners.
Mr. Cruikshank focuses on instrumentation/electronics, biotechnology, medical diagnostics & devices, semiconductors, nanotechnology, advanced materials, and information technologies. Since joining the company as an Associate in August 2007, he has supported the formation, investment, and growth of a number of companies. Mr. Cruikshank is a Director to Omniome and Encodia and an Observer to Arbor Biotechnologies, Genturi, Ultivue, Voxel8, Cytrellis Biosystems, 908 Devices, and Boreal Genomics. He previously led ARCH’s investment and was an Observer to Twist Bioscience (TWST). Mr. Cruikshank has participated and provided operating assistance to other companies including Ciespace (acquired by ESI), PixelEXX Systems, and Crystal IS (acquired by Asahi Kasei).
Mr. Cruikshank was formerly with Toshiba America Electronic Components as a Business Development Manager and was responsible for North American audio, video, and automotive semiconductor product lines with annual sales of $50 million. Prior to that, he was with Conexant Systems as an Industrial Engineer.
Mr. Cruikshank holds an M.B.A. with Honors from the University of Chicago, an M.S. in Industrial Engineering and Operations Research from University of California, Berkeley, and a B.S. in Mechanical Engineering from the University of California, Los Angeles, where he graduated Summa Cum Laude and was elected to Phi Beta Kappa.